Formosa and Rxilient ink deal for licensing APP13007

Formosa Pharmaceuticals has entered into a licensing agreement with Rxilient Medical for the exclusive commercialization of Byqlovi, an ophthalmic suspension containing clobetasol propionate, 0.05% (APP13007), across Southeast Asia. This agreement spans markets in Thailand, Singapore, the Philippines, and Indonesia, granting Rxilient the rights to distribute this patented drug. APP13007 is used for alleviating inflammation and pain following ocular surgery. The deal includes upfront payments and milestone-based payments tied to sales and regulatory approvals.

APP13007 incorporates clobetasol propionate, a highly potent corticosteroid, and utilizes Formosas advanced particle nanotech (APNT) nanoparticle formulation technology. Approved by the U.S. Food and Drug Administration (FDA) in 2024, this formulation offers a twice-daily dosage schedule over 14 days, delivering rapid and sustained relief for patients.

Erick Co, President and CEO of Formosa Pharmaceuticals, expressed enthusiasm about the partnership, stating: We are excited to collaborate with Rxilient, a key player with a strong regional presence and global experience. We believe that Rxilients network and dedication to innovative treatments will ensure the success of APP13007 in helping patients recover post-surgery.

Lawrence He, CEO of Rxilient, commented: Our mission at Rxilient is to provide high-quality therapies to address the needs of patients in our region. We are thrilled to partner with Formosa and introduce APP13007 to markets in Southeast Asia, offering vital solutions to individuals recovering from eye surgery.

Formosa Pharmaceuticals is a clinical-stage biotechnology company with a focus on oncology and ophthalmology. The companys APNT nanoparticle formulation technology, which was used to develop APP13007, improves the bioavailability and dissolution of active pharmaceutical ingredients for a variety of administration routes, including inhalers, topical treatments, and oral drugs. This technology enables the development of formulations with superior purity, stability, and uniformity, allowing for the effective delivery of potent or poorly soluble drugs to targeted tissues.

Author: Logan Reeves